Eva Ellebæk

Copenhagen University Hospital — Denmark

Medicine · Health Sciences

24h-index2.7kcitations148works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(71), Cancer Immunotherapy and Biomarkers(67), Immunotherapy and Immune Responses(60), Cutaneous Melanoma Detection and Management(30), Melanoma and MAPK Pathways(23)

Publications148 total

Impact of adjuvant anti-PD-1 immunotherapy on ovarian function in female patients with resectable melanoma: A prospective observational study
European Journal of Cancer·2026Open Access
BRAF/MEK inhibitor rechallenge in patients with non-resectable or metastatic BRAF V600-mutated melanoma: A stratified, controlled, retrospective EUMelaReg multicenter study
EJC Skin Cancer·2026Open Access
Discontinuation of BRAF/MEK inhibitor therapy after long-lasting response: Clinical outcomes in advanced melanoma
European Journal of Cancer·2025Open Access
Efficacy of combined BRAF-MEK inhibitor second-line therapy in patients with non-resectable or metastatic BRAFV600-positive melanoma after prior immunotherapy: A retrospective EUMelaReg multicenter study
EJC Skin Cancer·2025Open Access
514 Biomarker insights and long-term outcomes of TILT-123 oncolytic adenovirus combined with tumor-infiltrating lymphocytes in refractory metastatic melanoma: results from the TUNINTIL phase 1 trial
Regular and Young Investigator Award Abstracts·2025Open Access
Dabrafenib plus trametinib vs encorafenib plus binimetinib in <i>BRAF</i> -mutant metastatic melanoma: a real-world propensity score–matched survival analysis
JNCI Journal of the National Cancer Institute·2025
1642P The role of BRAF/MEKi rechallenge in BRAFV600 mutated melanoma patients: Insights from a EUMelaReg real-world study
Annals of Oncology·2025
1623P Impact of switching from BRAF/MEK inhibition to immune checkpoint inhibition before secondary resistance in metastatic melanoma: A EUMelaReg real-world study
Annals of Oncology·2025
1646P Efficiency of second-line BRAF/MEK inhibitors in BRAFV600 mutated metastatic melanoma patients after first-line immunotherapy failure: A EUMelaReg real-world study
Annals of Oncology·2025
1676P Early discontinuation of immunotherapy in patients with objective responses: Clinical outcomes in real-world Danish patients with advanced melanoma
Annals of Oncology·2025
1608P Fertility outcomes in young female patients treated with adjuvant anti-PD-1 therapy for resectable melanoma
Annals of Oncology·2025
1631P Clinical outcomes in patients with melanoma brain metastases: First-line treatment options
Annals of Oncology·2025
1547P Clinical outcomes of patients with acquired resistance to checkpoint inhibitors in melanoma, renal cell carcinoma and non-small cell lung cancer
Annals of Oncology·2025Open Access
1647P Dabrafenib/trametinib versus encorafenib/binimetinib in BRAF-mutant metastatic melanoma: A real-world propensity score matched survival analysis
Annals of Oncology·2025
1699eP Treatment patterns using encorafenib plus binimetinib in BRAF mutated melanoma patients
Annals of Oncology·2025
The Challenge of Treating Anti-PD-1-Resistant Advanced Melanoma
American Journal of Clinical Dermatology·2025
Neutralizing antibodies and lymphocyte count as biomarkers in patients receiving oncolytic adenovirus TILT-123 and adoptive cell transfer of tumor-infiltrating lymphocytes for metastatic melanoma refractory to immune checkpoint inhibitors.
Journal of Clinical Oncology·2025· 1 cited
Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab
British Journal of Cancer·2025· 3 citedOpen Access
Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma
European Journal of Cancer·2025· 2 citedOpen Access
Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case report
Melanoma Research·2025· 1 cited
page 1 of 8Next →

Frequent Co-authors

Inge Marie Svane(45), Marco Donia(30), Lars Bastholt(17), Henrik Schmidt(15), Mads Hald Andersen(14), Per thor Straten(12), Charlotte Aaquist Haslund(10), Rikke B. Holmstroem(9), Rikke Andersen(9), Trine Zeeberg Iversen(9), Özcan Met(8), Troels Holz Borch(7), Helle Westergren Hendel(7), Christina H. Ruhlmann(6), Lisbet Rosenkrantz Hölmich(5), Lotte Engell-Noerregaard(5), Sidsel Pedersen(5), Niels Junker(4), Sine Reker Hadrup(4), Morten Hansen(4)